Bernstein Lifts BioMarin Price Target as Valuation Case Strengthens Despite VOXZOGO Headwinds
Bernstein SocGen Group increased its price target on BioMarin Pharmaceutical Inc. (BMRN) to $94 from $90 and kept an Outperform rating, citing valuation upside even as the company navigates a softer-than-expected outlook for VOXZOGO and waits to provide guidance on the FOLD deal. Recent quarterly results showed mixed financials, and other firms hav…